Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine predictive value of Hammersmith score on Complete Cytogenetic Response (CCyR).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Dasatinib; Imatinib Mesylate

Criteria

Patients with Additional Chromosomal Anomalies (ACA) are accepted to be in CP. Patients enrolled in open-label clinical trials or other observational trials are also allowed (unless explicitly prohibited by the trial).

This trial does not prohibit participation in other observational trials.

Inclusion Criteria:

• Patients diagnosed with CP-CML. (ACA) are allowed

• Age >18 years old

• Prior treatment with imatinib monotherapy as first line treatment, to which the patient is deemed resistant or intolerant.Patients treated by INF and/or AraC prior (but not concomitant) to imatinib are eligible.

• Initiated with a 2G TKIs post-imatinib failure (resistance or intolerance) between 1-Jan-2005 and 30-Jun-2009.

Exclusion Criteria:

• Patients in (or with history of) accelerated or blastic phase CML

• Patients treated by allogeneic stem cell transplantation.

• Any other CML treatment except for INF and/or AraC,and a short period of Hydroxyurea or Anagrelide prior to imatinib.

• Patients treated with 2G TKI for reasons other than imatinib failure.

• Patients with no historical data (e.g. possibility of Sokal Score calculation) available.

• Patients participating in clinical or observational trials which explicitly prohibit enrollment in non interventional studies.